This company develops hormonal therapies targeting the underlying causes of gynecological cancers, particularly treatment-resistant ovarian cancer. Their drug development efforts aim to provide new treatment options and improve outcomes for women battling these cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Gynecological cancers, particularly ovarian cancer, often develop resistance to existing treatments, leading to limited options and poor outcomes for affected women. Current therapies may not effectively target the underlying causes of these cancers, resulting in recurrence and disease progression.
Solution
Kaida BioPharma is developing innovative hormonal therapies designed to target the root causes of treatment-resistant gynecological cancers. Their lead drug candidate, KAD101, is a growth hormone antagonist engineered to induce programmed cell death (autophagy) in gynecologic tumors. By targeting the specific needs of patients with these cancers, Kaida aims to provide a medical treatment that can make a significant difference in patient outcomes. The company's approach is based on research principles and clinical evidence demonstrating the efficacy of G129R, a growth hormone antagonist, in inducing programmed cell death in gynecologic tumors.
Target Audience
The primary target audience includes women battling treatment-resistant gynecological cancers, particularly ovarian cancer, and the healthcare professionals who treat them.
Features
- KAD101: A growth hormone antagonist designed to induce autophagy in gynecologic tumor cells.
- Targets treatment-resistant ovarian cancer.
- Based on the research and clinical evidence of G129R.
- Collaboration with leading researchers at Thomas Jefferson University and MD Anderson.
- Aims to provide a new hope for patients with gynecological cancers.